Novartis

News

Woman pushing man in wheelchair along beachfront as sun sets

Novartis pays $1bn upfront for Huntington's drug from PTC

Novartis has made a return to the Huntington's disease stage by licensing an oral mRNA splicer from PTC Therapeutics for $1 billion upfront.

News

Kisqali gets early breast cancer approval in Europe

Novartis' fast-growing breast cancer drug gets another growth driver as EU approves adjuvant use in patients with early-stage HR+, HER2- tumours

News

Gene therapy firm Kate Tx snapped up by Novartis for $1.1bn

Novartis buys gene therapy specialist Kate Therapeutics for $1.1 billion, adding an early-stage rival to Sarepta's muscular dystrophy therapy Elevidys

News

Novartis raises mid-term sales outlook on pipeline promise

Novartis has raised its guidance for sales growth out to 2029 on the strength of its pipeline and the potential of late-stage R&D assets

News

Novartis gets FDA okay for frontline use of Scemblix in CML

Novartis has picked up a new FDA approval for its chronic myeloid leukaemia therapy Scemblix that it believes is critical to unlocking the drug's blockbuster sales potential.

News

Novartis pays $150m upfront for Monte Rosa degrader drug

The lengthening list of pharma alliances focused on molecular glue degraders has another entry after Novartis signed a deal with Monte Rosa Therapeutics worth up to $2.2 billion.

Novartis pays $1bn upfront for Huntington's drug from PTC

Kisqali gets early breast cancer approval in Europe

Gene therapy firm Kate Tx snapped up by Novartis for $1.1bn

Novartis raises mid-term sales outlook on pipeline promise

Novartis gets FDA okay for frontline use of Scemblix in CML

Novartis pays $150m upfront for Monte Rosa degrader drug

DNA testing can help right racial imbalance in breast cancer

Using AI-driven synthetic personas to take your insights fur...

Novartis

Editor's Picks